Sign In
Buy AERI
$15.25
+0 (+0%)
At Close: Feb 17, 2023
Don't Look for Alcon's Acquisition to Boost Share Price in Short Term
04:02pm, Wednesday, 24'th Aug 2022
Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Aerie Pharmaceuticals, Inc. Buyout
03:15pm, Wednesday, 24'th Aug 2022
Wilmington, Delaware--(Newsfile Corp. - August 24, 2022) - Rigrodsky Law, P.A. is investigating Aerie Pharmaceuticals, Inc. ("Aerie") (NASDAQ: AERI) regarding possible breaches of fiduciary duties and
AERI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Aerie Pharmaceuticals, Inc. Is Fair to Shareholders
08:19am, Wednesday, 24'th Aug 2022
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) to Alcon for $15.25 per share is fair to Aerie
SHAREHOLDER ALERT: Weiss Law Investigates Aerie Pharmaceuticals, Inc.
03:20pm, Tuesday, 23'rd Aug 2022
NEW YORK , Aug. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerie Pharmaceuticals, Inc. ("Aerie"
Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up
12:47pm, Tuesday, 23'rd Aug 2022
Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.
Alcon to Acquire Aerie Pharmaceuticals for $15.25 a Share
03:45am, Tuesday, 23'rd Aug 2022
Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share.
After Golden Cross, Aerie Pharmaceuticals (AERI)'s Technical Outlook is Bright
11:17am, Wednesday, 17'th Aug 2022
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Aerie Pharmaceuticals, Inc.'s (AERI) CEO Raj Kannan on Q2 2022 Results - Earnings Call Transcript
09:49am, Sunday, 07'th Aug 2022
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Hans Vitzthum – Investor Relations Raj Kannan – Chief Executive Officer P
Aerie (AERI) Q2 Loss Narrower Than Expected, Sales Beat
01:33pm, Friday, 05'th Aug 2022
Aerie (AERI) Q2 loss narrows year over year and revenues beat estimates in the second quarter of 2022.
Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Thursday, 04'th Aug 2022
Aerie (AERI) delivered earnings and revenue surprises of 38.46% and 2.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies,
Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease
04:03pm, Wednesday, 25'th May 2022
Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.
Aerie Pharmaceuticals' (AERI) CEO Raj Kannan on Q1 2022 Results - Earnings Call Transcript
03:48am, Saturday, 07'th May 2022
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Hans Vitzthum – LifeSci Partners Raj Kannan – Chief Executive Officer Gary S
Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
05:18pm, Friday, 06'th May 2022
Aerie (AERI) misses on both earnings and revenues for the first quarter of 2022.
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Misses Revenue Estimates
07:34pm, Thursday, 05'th May 2022
Aerie (AERI) delivered earnings and revenue surprises of -1.54% and 1.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
